Markus Peck-Radosavljevic, MD, is Associate Professor of Medicine and
Vice-Chairman at the Department of Gastroenterology and Hepatology at the
Medizinische Universität Wien (MedUniWien), Austria. He is a fellow of the
Austrian College of Physicians (Internal Medicine, Gastroenterology /
Hepatology, Infectious Diseases, and Intensive Care Medicine) and member of
several professional organisations including the American Association for the
Study of Liver Disease (AASLD), the European Association for the Study of the
Liver (EASL), the American Gastroenterologic Association (AGA), the Austrian
Transplant Association, the Austrian Society for Infectious Diseases, and the
Austrian Association for Gastroenterology and Hepatology. Prof. Peck is
currently the Secretary General of the Austrian Association for Internal
Prof. Peck started out his research in liver disease with the complications of portal hypertension and cirrhosis including the hematologic abnormalities. He has published several reports on thrombocytopenia and thrombopoietin in liver disease and liver transplantation and later more on the hematologic side effects of antiviral therapy in chronic hepatitis C. He has been co-investigator in trial of pegInterferon in liver transplant patients and principal investigator in trials of pegIFN in hemodialysis patients with chronic hepatitis C or combination antiviral therapy in HIV/HCV coinfected patients.
For the last several years, he has been heading the Portal Hypertension as well as the HCC Study Group at the MedUniWien. Currently he is engaged in mostly clinical but also some basic research in advanced stage liver disease, including problems related to portal hypertension, viral hepatitis, and hepatocellular carcinoma, where he is conducting several clinical trials.